A start-up company in New Haven led by two Israelis will collaborate with Yale School of Medicine to bring the latest diagnostic advances in cancer research from Yale to oncologists who treat cancer patients. Precipio Diagnostics, led by CEO Ilan Danieli and CFO Gil Alon, both of Israel, is in the vanguard of the personalized medicine revolution, bringing scientific breakthroughs to the broader market where diagnostic developments can reach more oncology practices.